Highlights nieuwsbrief 2
This newsletter presents you the following key sessions:
2. Confirmed overall survival benefit of obinutuzumab in combination with chlorambucil in patients
with previously untreated CLL and comorbidities
3. Quizartinib prolongs overall survival in patients with FLT3-internal tandem duplication–mutated
relapsed/refractory AML in the phase III QuANTUM-R trial
4. ELOQUENT-3: Elotuzumab plus pomalidomide/dexamethasone (EPd) shows favorable results over
Pd for treatment of relapsed/refractory multiple myeloma
5. Early PET-driven treatment de-escalation can safely guide subsequent treatment in patients with
advanced Hodgkin lymphoma